Summary

In 2024, the global market size of Biologics and Biosimilars was estimated to be worth US$ 441320 million and is forecast to reach approximately US$ 784010 million by 2031 with a CAGR of 8.7% during the forecast period 2025-2031.

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.

Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.

The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biologics and Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Biologics and Biosimilars in global and regional level.
Chapter 3: Detailed analysis of Biologics and Biosimilars company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics and Biosimilars revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Biologics and Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Biologics and Biosimilars Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Biologics and Biosimilars Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biologics and Biosimilars Market Size Estimates and Forecasts
2.2 Biologics and Biosimilars Market Size by Region: 2024 Versus 2031
2.2.1 Global Biologics and Biosimilars Revenue by Region: 2020-2025
2.2.2 Global Biologics and Biosimilars Revenue Forecast by Region (2026-2031)
2.2.3 Global Biologics and Biosimilars Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Biologics and Biosimilars Revenue by Type (2020-2031)
3.1.2 Global Biologics and Biosimilars Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Biologics and Biosimilars Revenue by Application (2020-2031)
3.2.2 Global Biologics and Biosimilars Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Monoclonal Antibodies of Biologics and Biosimilars Revenue Market Share by Application
3.3.2 Interferon of Biologics and Biosimilars Revenue Market Share by Application
3.3.3 Insulin of Biologics and Biosimilars Revenue Market Share by Application
3.3.4 Vaccines of Biologics and Biosimilars Revenue Market Share by Application
3.3.5 Others of Biologics and Biosimilars Revenue Market Share by Application
4 Global Biologics and Biosimilars by Company
4.1 Global Biologics and Biosimilars Revenue by Company (2020-2025)
4.2 Global Biologics and Biosimilars Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Biologics and Biosimilars Companies around the World: Ranking by Revenue
4.3.2 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Biologics and Biosimilars Companies Headquarters & Product Type
4.4.1 Global Biologics and Biosimilars Companies Headquarters
4.4.2 Date of International Companies Enter into Biologics and Biosimilars Market
4.4.3 Global Biologics and Biosimilars Companies Product & Service
4.4.4 Monoclonal Antibodies Revenue Market Share of Biologics and Biosimilars by Company
4.4.5 Interferon Revenue Market Share of Biologics and Biosimilars by Company
4.4.6 Insulin Revenue Market Share of Biologics and Biosimilars by Company
4.4.7 Vaccines Revenue Market Share of Biologics and Biosimilars by Company
4.4.8 Others Revenue Market Share of Biologics and Biosimilars by Company
4.5 Global Biologics and Biosimilars Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Roche
5.1.1 Roche Corporation Information
5.1.2 Roche Description, Business Overview
5.1.3 Roche Biologics and Biosimilars Products Offered
5.1.4 Roche Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.1.5 Roche Biologics and Biosimilars Revenue by Product in 2024
5.1.6 Roche Biologics and Biosimilars Revenue by Application in 2024
5.1.7 Roche Biologics and Biosimilars Revenue by Geographic Area in 2024
5.1.8 Roche Recent Developments
5.2 Amgen
5.2.1 Amgen Corporation Information
5.2.2 Amgen Description, Business Overview
5.2.3 Amgen Biologics and Biosimilars Products Offered
5.2.4 Amgen Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.2.5 Amgen Biologics and Biosimilars Revenue by Product in 2024
5.2.6 Amgen Biologics and Biosimilars Revenue by Application in 2024
5.2.7 Amgen Biologics and Biosimilars Revenue by Geographic Area in 2024
5.2.8 Amgen Recent Developments
5.3 AbbVie
5.3.1 AbbVie Corporation Information
5.3.2 AbbVie Description, Business Overview
5.3.3 AbbVie Biologics and Biosimilars Products Offered
5.3.4 AbbVie Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.3.5 AbbVie Biologics and Biosimilars Revenue by Product in 2024
5.3.6 AbbVie Biologics and Biosimilars Revenue by Application in 2024
5.3.7 AbbVie Biologics and Biosimilars Revenue by Geographic Area in 2024
5.3.8 AbbVie Recent Developments
5.4 Sanofi
5.4.1 Sanofi Corporation Information
5.4.2 Sanofi Description, Business Overview
5.4.3 Sanofi Biologics and Biosimilars Products Offered
5.4.4 Sanofi Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.4.5 Sanofi Biologics and Biosimilars Revenue by Product in 2024
5.4.6 Sanofi Biologics and Biosimilars Revenue by Application in 2024
5.4.7 Sanofi Biologics and Biosimilars Revenue by Geographic Area in 2024
5.4.8 Sanofi Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Corporation Information
5.5.2 Johnson & Johnson Description, Business Overview
5.5.3 Johnson & Johnson Biologics and Biosimilars Products Offered
5.5.4 Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.5.5 Johnson & Johnson Biologics and Biosimilars Revenue by Product in 2024
5.5.6 Johnson & Johnson Biologics and Biosimilars Revenue by Application in 2024
5.5.7 Johnson & Johnson Biologics and Biosimilars Revenue by Geographic Area in 2024
5.5.8 Johnson & Johnson Recent Developments
5.6 Pfizer
5.6.1 Pfizer Corporation Information
5.6.2 Pfizer Description, Business Overview
5.6.3 Pfizer Biologics and Biosimilars Products Offered
5.6.4 Pfizer Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.6.5 Pfizer Biologics and Biosimilars Revenue by Product in 2024
5.6.6 Pfizer Biologics and Biosimilars Revenue by Application in 2024
5.6.7 Pfizer Biologics and Biosimilars Revenue by Geographic Area in 2024
5.6.8 Pfizer Recent Developments
5.7 Novo Nordisk
5.7.1 Novo Nordisk Corporation Information
5.7.2 Novo Nordisk Description, Business Overview
5.7.3 Novo Nordisk Biologics and Biosimilars Products Offered
5.7.4 Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.7.5 Novo Nordisk Biologics and Biosimilars Revenue by Product in 2024
5.7.6 Novo Nordisk Biologics and Biosimilars Revenue by Application in 2024
5.7.7 Novo Nordisk Biologics and Biosimilars Revenue by Geographic Area in 2024
5.7.8 Novo Nordisk Recent Developments
5.8 Eli Lilly
5.8.1 Eli Lilly Corporation Information
5.8.2 Eli Lilly Description, Business Overview
5.8.3 Eli Lilly Biologics and Biosimilars Products Offered
5.8.4 Eli Lilly Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.8.5 Eli Lilly Biologics and Biosimilars Revenue by Product in 2024
5.8.6 Eli Lilly Biologics and Biosimilars Revenue by Application in 2024
5.8.7 Eli Lilly Biologics and Biosimilars Revenue by Geographic Area in 2024
5.8.8 Eli Lilly Recent Developments
5.9 Novartis
5.9.1 Novartis Corporation Information
5.9.2 Novartis Description, Business Overview
5.9.3 Novartis Biologics and Biosimilars Products Offered
5.9.4 Novartis Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.9.5 Novartis Biologics and Biosimilars Revenue by Product in 2024
5.9.6 Novartis Biologics and Biosimilars Revenue by Application in 2024
5.9.7 Novartis Biologics and Biosimilars Revenue by Geographic Area in 2024
5.9.8 Novartis Recent Developments
5.10 Merck
5.10.1 Merck Corporation Information
5.10.2 Merck Description, Business Overview
5.10.3 Merck Biologics and Biosimilars Products Offered
5.10.4 Merck Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.10.5 Merck Biologics and Biosimilars Revenue by Product in 2024
5.10.6 Merck Biologics and Biosimilars Revenue by Application in 2024
5.10.7 Merck Biologics and Biosimilars Revenue by Geographic Area in 2024
5.10.8 Merck Recent Developments
5.11 Biogen
5.11.1 Biogen Corporation Information
5.11.2 Biogen Description, Business Overview
5.11.3 Biogen Biologics and Biosimilars Products Offered
5.11.4 Biogen Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.11.5 Biogen Biologics and Biosimilars Revenue by Product in 2024
5.11.6 Biogen Biologics and Biosimilars Revenue by Application in 2024
5.11.7 Biogen Biologics and Biosimilars Revenue by Geographic Area in 2024
5.11.8 Biogen Recent Developments
5.12 Celltrion
5.12.1 Celltrion Corporation Information
5.12.2 Celltrion Description, Business Overview
5.12.3 Celltrion Biologics and Biosimilars Products Offered
5.12.4 Celltrion Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.12.5 Celltrion Biologics and Biosimilars Revenue by Product in 2024
5.12.6 Celltrion Biologics and Biosimilars Revenue by Application in 2024
5.12.7 Celltrion Biologics and Biosimilars Revenue by Geographic Area in 2024
5.12.8 Celltrion Recent Developments
5.13 Sobi
5.13.1 Sobi Corporation Information
5.13.2 Sobi Description, Business Overview
5.13.3 Sobi Biologics and Biosimilars Products Offered
5.13.4 Sobi Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.13.5 Sobi Biologics and Biosimilars Revenue by Product in 2024
5.13.6 Sobi Biologics and Biosimilars Revenue by Application in 2024
5.13.7 Sobi Biologics and Biosimilars Revenue by Geographic Area in 2024
5.13.8 Sobi Recent Developments
5.14 3SBIO
5.14.1 3SBIO Corporation Information
5.14.2 3SBIO Description, Business Overview
5.14.3 3SBIO Biologics and Biosimilars Products Offered
5.14.4 3SBIO Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.14.5 3SBIO Biologics and Biosimilars Revenue by Product in 2024
5.14.6 3SBIO Biologics and Biosimilars Revenue by Application in 2024
5.14.7 3SBIO Biologics and Biosimilars Revenue by Geographic Area in 2024
5.14.8 3SBIO Recent Developments
5.15 Changchun High Tech
5.15.1 Changchun High Tech Corporation Information
5.15.2 Changchun High Tech Description, Business Overview
5.15.3 Changchun High Tech Biologics and Biosimilars Products Offered
5.15.4 Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.15.5 Changchun High Tech Biologics and Biosimilars Revenue by Product in 2024
5.15.6 Changchun High Tech Biologics and Biosimilars Revenue by Application in 2024
5.15.7 Changchun High Tech Biologics and Biosimilars Revenue by Geographic Area in 2024
5.15.8 Changchun High Tech Recent Developments
5.16 Kanghong Pharma
5.16.1 Kanghong Pharma Corporation Information
5.16.2 Kanghong Pharma Description, Business Overview
5.16.3 Kanghong Pharma Biologics and Biosimilars Products Offered
5.16.4 Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.16.5 Kanghong Pharma Biologics and Biosimilars Revenue by Product in 2024
5.16.6 Kanghong Pharma Biologics and Biosimilars Revenue by Application in 2024
5.16.7 Kanghong Pharma Biologics and Biosimilars Revenue by Geographic Area in 2024
5.16.8 Kanghong Pharma Recent Developments
5.17 Innovent Biologics
5.17.1 Innovent Biologics Corporation Information
5.17.2 Innovent Biologics Description, Business Overview
5.17.3 Innovent Biologics Biologics and Biosimilars Products Offered
5.17.4 Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.17.5 Innovent Biologics Biologics and Biosimilars Revenue by Product in 2024
5.17.6 Innovent Biologics Biologics and Biosimilars Revenue by Application in 2024
5.17.7 Innovent Biologics Biologics and Biosimilars Revenue by Geographic Area in 2024
5.17.8 Innovent Biologics Recent Developments
5.18 Gan&Lee
5.18.1 Gan&Lee Corporation Information
5.18.2 Gan&Lee Description, Business Overview
5.18.3 Gan&Lee Biologics and Biosimilars Products Offered
5.18.4 Gan&Lee Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.18.5 Gan&Lee Biologics and Biosimilars Revenue by Product in 2024
5.18.6 Gan&Lee Biologics and Biosimilars Revenue by Application in 2024
5.18.7 Gan&Lee Biologics and Biosimilars Revenue by Geographic Area in 2024
5.18.8 Gan&Lee Recent Developments
5.19 Tonghua Dongbao
5.19.1 Tonghua Dongbao Corporation Information
5.19.2 Tonghua Dongbao Description, Business Overview
5.19.3 Tonghua Dongbao Biologics and Biosimilars Products Offered
5.19.4 Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.19.5 Tonghua Dongbao Biologics and Biosimilars Revenue by Product in 2024
5.19.6 Tonghua Dongbao Biologics and Biosimilars Revenue by Application in 2024
5.19.7 Tonghua Dongbao Biologics and Biosimilars Revenue by Geographic Area in 2024
5.19.8 Tonghua Dongbao Recent Developments
5.20 United Laboratory
5.20.1 United Laboratory Corporation Information
5.20.2 United Laboratory Description, Business Overview
5.20.3 United Laboratory Biologics and Biosimilars Products Offered
5.20.4 United Laboratory Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
5.20.5 United Laboratory Biologics and Biosimilars Revenue by Product in 2024
5.20.6 United Laboratory Biologics and Biosimilars Revenue by Application in 2024
5.20.7 United Laboratory Biologics and Biosimilars Revenue by Geographic Area in 2024
5.20.8 United Laboratory Recent Developments
6 North America
6.1 North America Biologics and Biosimilars Market Size YoY Growth 2020-2031
6.2 North America Biologics and Biosimilars Market Facts & Figures by Country (2020-2031)
6.3 North America Biologics and Biosimilars Revenue by Type (2020-2025)
6.4 North America Biologics and Biosimilars Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Biologics and Biosimilars Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Biologics and Biosimilars Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Biologics and Biosimilars Revenue by Type (2020-2025)
7.4 Asia-Pacific Biologics and Biosimilars Revenue by Application (2020-2025)
8 Europe
8.1 Europe Biologics and Biosimilars Market Size YoY Growth 2020-2031
8.2 Europe Biologics and Biosimilars Market Facts & Figures by Country (2020-2031)
8.3 Europe Biologics and Biosimilars Revenue by Type (2020-2025)
8.4 Europe Biologics and Biosimilars Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Biologics and Biosimilars Market Size YoY Growth 2020-2031
9.2 Latin America Biologics and Biosimilars Market Facts & Figures by Country (2020-2031)
9.3 Latin America Biologics and Biosimilars Revenue by Type (2020-2025)
9.4 Latin America Biologics and Biosimilars Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Biologics and Biosimilars Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Biologics and Biosimilars Revenue by Type (2020-2025)
10.4 Middle East and Africa Biologics and Biosimilars Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Biologics and Biosimilars Supply Chain Analysis
11.2 Biologics and Biosimilars Key Raw Materials and Upstream Suppliers
11.3 Biologics and Biosimilars Clients Analysis
11.4 Biologics and Biosimilars Sales Channel and Sales Model Analysis
11.4.1 Biologics and Biosimilars Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Biologics and Biosimilars Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Biologics and Biosimilars Distributors
12 Biologics and Biosimilars Market Dynamics
12.1 Biologics and Biosimilars Industry Trends
12.2 Biologics and Biosimilars Market Drivers
12.3 Biologics and Biosimilars Market Challenges
12.4 Biologics and Biosimilars Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer